Back to Search
Start Over
Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Oct 07; Vol. 12, pp. 725447. Date of Electronic Publication: 2021 Oct 07 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Introduction: There is an urgent medical need to differentiate active tuberculosis (ATB) from latent tuberculosis infection (LTBI) and prevent undertreatment and overtreatment. The aim of this study was to identify biomarker profiles that may support the differentiation between ATB and LTBI and to validate these signatures.<br />Materials and Methods: The discovery cohort included adult individuals classified in four groups: ATB (n = 20), LTBI without prophylaxis (untreated LTBI; n = 20), LTBI after completion of prophylaxis (treated LTBI; n = 20), and healthy controls (HC; n = 20). Their sera were analyzed for 40 cytokines/chemokines and activity of adenosine deaminase (ADA) isozymes. A prediction model was designed to differentiate ATB from untreated LTBI using sparse partial least squares (sPLS) and logistic regression analyses. Serum samples of two independent cohorts (national and international) were used for validation.<br />Results: sPLS regression analyses identified C-C motif chemokine ligand 1 (CCL1), C-reactive protein (CRP), C-X-C motif chemokine ligand 10 (CXCL10), and vascular endothelial growth factor (VEGF) as the most discriminating biomarkers. These markers and ADA(2) activity were significantly increased in ATB compared to untreated LTBI (p ≤ 0.007). Combining CCL1, CXCL10, VEGF, and ADA2 activity yielded a sensitivity and specificity of 95% and 90%, respectively, in differentiating ATB from untreated LTBI. These findings were confirmed in the validation cohort including remotely acquired untreated LTBI participants.<br />Conclusion: The biomarker signature of CCL1, CXCL10, VEGF, and ADA2 activity provides a promising tool for differentiating patients with ATB from non-treated LTBI individuals.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer HD declared a past co-authorship with the authors SJ and TO to the handling editor.<br /> (Copyright © 2021 Delemarre, van Hoorn, Bossink, Drylewicz, Joosten, Ottenhoff, Akkerman, Goletti, Petruccioli, Navarra, van den Broek, Paardekooper, van Haeften, Koenderman, Lammers, Thijsen, Hofland and Nierkens.)
- Subjects :
- Adult
Biomarkers blood
Case-Control Studies
Cohort Studies
Cross-Sectional Studies
Female
Humans
Immunologic Tests
Latent Tuberculosis diagnosis
Latent Tuberculosis immunology
Logistic Models
Male
Middle Aged
Overtreatment prevention & control
Sensitivity and Specificity
Young Adult
Adenosine Deaminase blood
Chemokine CCL1 blood
Chemokine CXCL10 blood
Latent Tuberculosis blood
Vascular Endothelial Growth Factor A blood
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 34691031
- Full Text :
- https://doi.org/10.3389/fimmu.2021.725447